NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Insmed Incorporated INSM
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$606.4M
▲ 66.7% vs FY2024
EPS · FY25
$-6.42
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-249.3%
Net margin · FY25
-210.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 606.4M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 211 cents on every revenue dollar this year.
Per share
USD -6.42
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-249.3%
Return on equity, FY2025
ROE
Operating margin-205.6%
Net margin-210.5%
Return on assets-59.5%
Each USD of equity lost 249 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+29.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+35.2%
+29.8%
+34.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.21B
Shares outstanding, FY2025
Change, 5 years+108.5%
Change, 10 years+246.6%
The share count grew 108% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.3B
total assets, end of FY2025
Total assetsUSD 2.3B
EquityUSD 739.0M
CashUSD 510.4M
Gross debtUSD 541.0M
Net debtUSD 30.5M
Current ratio3.83×
Net debt stands at 4% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.6
0.4
0.3
0.2
0.2
0.2
0.1
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
Operating income $B
−1.2
−0.9
−0.7
−0.5
−0.4
−0.3
−0.2
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
EBITDA $B
−1.2
−0.9
−0.7
−0.5
−0.4
−0.3
−0.2
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
Net income $B
−1.3
−0.9
−0.7
−0.5
−0.4
−0.3
−0.3
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.1
−0.0
0.1
EPS, diluted $
−6.42
−5.57
−5.34
−3.91
−3.88
−3.01
−3.01
−4.22
−2.89
−2.85
−2.02
−1.84
−1.60
−1.56
−2.95
−0.49
9.30
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−249.3
·
·
−193.2
−126.7
−109.4
−108.2
−113.9
−74.7
−75.6
−47.5
−48.0
−42.4
−32.4
−36.5
−4.1
95.5
Shares out B
0.21
0.18
0.15
0.14
0.12
0.10
0.09
0.08
0.08
0.06
0.06
0.05
0.04
0.03
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
52 of 52
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed